Blog
RSS FeedPosted by Michael Wonder on 09 Sep 2022
B.C. family grateful for expanded funding to cystic fibrosis drug, but questions why it took so long
7 September 2022 - B.C. is last Canadian jurisdiction to fund Trikafta for patients with cystic fibrosis age 6 to 11. ...
Posted by Michael Wonder on 08 Sep 2022
British Colombia expands children’s access to ‘transformational’ cystic fibrosis drug
7 September 2022 - A week after a B.C. family went public with its plea for a life-changing drug for ...
Posted by Michael Wonder on 07 Sep 2022
Ongoing uncertainty about prices will deter new drug launches in Canada
7 September 2022 - Further delays in access or complete denials of access to innovative drugs will hurt even more Canadians ...
Posted by Michael Wonder on 30 Aug 2022
Yukon woman paid $7,000 for private ketamine treatment, only to learn that the Yukon Government covers it
29 August 2022 - Evelyn Larson visited a private clinic in Saskatoon only to find the Yukon did cover the treatment ...
Posted by Michael Wonder on 30 Jul 2022
Amylyx Pharmaceuticals announces Albrioza is now available in Canada for the treatment of amyotrophic lateral sclerosis
29 July 2022 - Amylyx Pharmaceuticals today announced that Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) is now commercially available in Canada for ...
Posted by Michael Wonder on 18 Jul 2022
More children now eligible for cystic fibrosis drug
18 July 2022 - Effective today, the Province will pay for the cystic fibrosis drug Trikafta for children aged six to ...
Posted by Michael Wonder on 13 Jul 2022
Canada making progress in prescription drug coverage
13 July 2022 - Canada has seen a significant improvement in the number of Canadians eligible for some form of prescription ...
Posted by Michael Wonder on 12 Jul 2022
Alberta expands access to cystic fibrosis drug Trikafta for children 6 to 11
11 July 2022 - Children with cystic fibrosis can now live 'longer, healthier and fuller lives,' says advocate. ...
Posted by Michael Wonder on 07 Jul 2022
Vertex announces letter of intent with the pan-Canadian Pharmaceutical Alliance for public reimbursement of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis ages 6 and older
7 July 2022 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical ...
Posted by Michael Wonder on 24 May 2022
HLS Therapeutics obtains public reimbursement for Vascepa in Quebec
24 May 2022 - Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with ...
Posted by Michael Wonder on 17 May 2022
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s Ajovy (fremanezumab), for the preventive treatment of migraine in adults
17 May 2022 - Teva Canada welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, ...
Posted by Michael Wonder on 03 May 2022
Boehringer Ingelheim Canada announces reimbursement for Ofev (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases
3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, ...
Posted by Michael Wonder on 28 Apr 2022
Market for new medicines in Canada has not slowed over last two years, despite focus on COVID-19 treatments
28 April 2022 - An average of nine new medicines per quarter have been approved in Canada through the pandemic, ...
Posted by Michael Wonder on 28 Apr 2022
Baqsimi (nasal glucagon), rescue treatment for severe hypoglycaemia now covered in British Colombia, Alberta & Saskatchewan
27 April 2022 - Lilly Canada is pleased to announce that as of 5 April 2022, Baqsimi (glucagon nasal powder) ...
Posted by Michael Wonder on 26 Apr 2022
Amarin partner HLS Therapeutics completes reimbursement negotiations with Pan-Canadian Pharmaceutical Alliance for Vascepa (icosapent ethyl)
26 April 2022 - Amarin Corporation announced today its partner HLS Therapeutics has completed negotiations with Canada’s pan-Canadian Pharmaceutical Alliance for ...